MedTrace Logo

A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD

NCT03953079 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2022-01-19

Study results available
· View outcomes & findings →

Summary

Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels of GB-102 compared with aflibercept.

Conditions

  • Neovascular Age-Related Macular Degeneration

Interventions

DRUG

Drug: GB-102

Intravitreal injection of GB-102

DRUG

Aflibercept

Intravitreal injection of aflibercept (2 mg dose)

Sponsors & Collaborators

  • Graybug Vision

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Graybug Vision, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-26
Primary Completion
2020-12-15
Completion
2021-06-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03953079 on ClinicalTrials.gov